Kratom Consumption - The Tales of Three Patients.

The rising prevalence of kratom use in the United States has led to increased encounters with individuals who consume kratom and those who develop Kratom Use Disorder (KUD) among healthcare professionals. This case series highlights the need for diverse treatment approaches tailored to the individual motivations for kratom consumption. Three cases are presented: one involving the progression from kratom use for energy to opioid-driven use with subsequent challenges in detoxification and transition to naltrexone necessitating buprenorphine low-dose induction for maintenance; another detailing successful inpatient detoxification using methadone and symptom-driven clonidine, followed by successful maintenance treatment with naltrexone; and a final case involving kratom consumption for pain and anxiety self-management by an individual without a history of addictive disorders, without meeting KUD criteria.

Prevalence of Kratom Use Disorder Among Kratom Consumers.

Objectives: Kratom leaf products are increasingly consumed in the United States, with many consumers reporting they experience beneficial effects from kratom use. However, there is a growing concern for kratom's potential to result in dependence when used regularly. As such, we sought to assess, using Diagnostic and Statistical Manual of Mental Disorders , (DSM-5) , diagnostic criteria for substance use disorder, the prevalence of "kratom use disorder" (KUD) among kratom consumers.

The New Hampshire Hospital Screening and Referral Algorithm (NHHSRA) for Substance Use in People With Serious Mental Illness.

Substance use is a common co-occurrence among psychiatrically hospitalized adults, yet it is especially difficult to identify in those with serious mental illness. Existing screening instruments are not feasible for individuals with serious mental illness, as they rely heavily on subjective self-report. This study aimed to develop and validate an objective substance use screening instrument for use in seriously mentally ill patient populations.

Evaluating health information provided to kratom consumers by good manufacturing practice-qualified vendors.

Background: "Kratom" commonly refers to the botanical Mitragyna speciosa, native to Southeast Asia, which is increasingly used globally for its unique pharmacological effects. Motives for using the whole plant material or kratom-derived products include self-management of pain, mental health disorders, symptoms related to substance use disorders, and/or to increase energy. In the United States, kratom products have varying alkaloid content, potencies, and marketing profiles.

The Impact of THC and CBD in Schizophrenia: A Systematic Review.

People with schizophrenia are more likely to develop cannabis use disorder (CUD) and experience worse outcomes with use. Yet as cannabis is legalized for medical and recreational use, there is interest in its therapeutic potential. To conduct a systematic review summarizing the design and results of controlled trials using defined doses of THC and CBD in schizophrenia.

Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review.

Objective: Two primary compounds of the cannabis plant (), delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), differentially and dose-dependently affect mood and anxiety. In this systematic review, the authors summarize the design and results of controlled trials assessing the effects of THC and CBD on affective disorders, anxiety disorders, and posttraumatic stress disorder (PTSD).

Methods: A keyword search of eight online literature databases identified eight randomized controlled trials of defined CBD or THC doses for the target populations.

Palladium-catalyzed allylic substitution with (η6-arene-CH2Z)Cr(CO)(3)-based nucleophiles.

Although the palladium-catalyzed Tsuji-Trost allylic substitution reaction has been intensively studied, there is a lack of general methods to employ simple benzylic nucleophiles. Such a method would facilitate access to "α-2-propenyl benzyl" motifs, which are common structural motifs in bioactive compounds and natural products. We report herein the palladium-catalyzed allylation reaction of toluene-derived pronucleophiles activated by tricarbonylchromium.

Synthesis and structural characterization of a series of dimeric metal(II) imido complexes {M(mu-NAr(#))}2 [M = Ge, Sn, Pb; Ar(#) = C6H3-2,6-(C6H2-2,4,6-Me3)2] and the related monomeric primary amido derivatives M{N(H)Ar(#)}2 (M = Ge, Sn, Pb): spectroscopic manifestations of secondary metal-ligand interactions.

The solvent-free reaction of M{N(SiMe(3))(2)}(2) (M = Ge, Sn, or Pb) with the sterically encumbered primary amine 2,6-dimesitylaniline Ar(#)NH(2) [Ar(#) = C(6)H(3)-2,6(C(6)H(2)-2,4,6-Me(3))(2)] at ca. 165-175 degrees C afforded the highly colored imido dimers {M(mu-NAr(#))}(2), where M = Ge (1), Sn (2), or Pb (3), with disilylamine elimination. The compounds were characterized by single-crystal X-ray crystallography and heteronuclear NMR spectroscopy.

Mechanistic detail revealed via comprehensive kinetic modeling of [rac-C(2)H4(1-indenyl)2ZrMe2]-catalyzed 1-hexene polymerization.

Thorough kinetic characterization of single-site olefin polymerization catalysis requires comprehensive, quantitative kinetic modeling of a rich multiresponse data set that includes monomer consumption, molecular weight distributions (MWDs), end group analysis, etc. at various conditions. Herein we report the results obtained via a comprehensive, quantitative kinetic modeling of all chemical species in the batch polymerization of 1-hexene by rac-C(2)H(4)(1-Ind)(2)ZrMe(2) activated with B(C(6)F(5))(3).

C(aryl)-O activation of aryl carboxylates in nickel-catalyzed biaryl syntheses.

Crucial breakthroughs in the activation of the C(aryl)-O bond of phenol derivatives were achieved almost simultaneously by two research groups (see scheme; Cy = cyclohexyl). Garg et al. coupled a range of aryl pivalates with arylboronic acids to give unsymmetrical biaryls.

Synthesis and Characterization of Ge(II), Sn(II), and Pb(II) Monoamides with -NH2 Ligands.

The synthesis and characterization of the first divalent germanium, tin, and lead monoamide derivatives of the parent amide group -NH(2) are presented. They have the general formula (ArMNH(2))(2) (M = Ge, Ar = Ar'(C(6)H(3)-2,6-Pr(i)(2)) or Ar* (C(6)H(3)-2,6(C(6)H(2)-2,4,6-Pr(i)(3))); M = Sn, Ar = Ar*; M = Pb, Ar = Ar*). For germanium and tin, they were obtained by reacting the corresponding terphenyl halides of the group 14 elements with liquid ammonia in diethyl ether.

Characterization of Ar'Sn(micro-Br)Sn(Ar')CH2C6H4-4-Pri (Ar' = C6H3-2,6-Dipp2; Dipp = C6H3-2,6-Pri2): a stable structural analogue for a heavier group 14 element monobridged alkene isomer HM(micro-H)MH2 (M = Sn or Pb).

The title compound is the first stable structural analogue for the monobridged isomer of a heavier group 14 alkene analogue.